MX2021003681A - Composiciones y metodos para el tratamiento de desordenes inflamatorios. - Google Patents

Composiciones y metodos para el tratamiento de desordenes inflamatorios.

Info

Publication number
MX2021003681A
MX2021003681A MX2021003681A MX2021003681A MX2021003681A MX 2021003681 A MX2021003681 A MX 2021003681A MX 2021003681 A MX2021003681 A MX 2021003681A MX 2021003681 A MX2021003681 A MX 2021003681A MX 2021003681 A MX2021003681 A MX 2021003681A
Authority
MX
Mexico
Prior art keywords
treatment
inflammatory disorders
benzimidazole derivative
patient
compound
Prior art date
Application number
MX2021003681A
Other languages
English (en)
Inventor
Hariharan Venkatesan
Michael Rabinowitz
Mark D Rosen
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of MX2021003681A publication Critical patent/MX2021003681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan aquí métodos de tratamiento y prevención del padecimiento inflamatorio del intestino en un paciente. Los métodos aquí provistos comprenden administrar al paciente que lo necesite una cantidad efectiva de un compuesto de benzoimidazol, Compuesto 1, para tratar o prevenir un padecimiento inflamatorio del intestino en un paciente. También se proporcionan formulaciones y rutas de administración del compuesto.
MX2021003681A 2018-10-03 2019-10-02 Composiciones y metodos para el tratamiento de desordenes inflamatorios. MX2021003681A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862740748P 2018-10-03 2018-10-03
PCT/US2019/054293 WO2020072645A1 (en) 2018-10-03 2019-10-02 Benzimidazole derivative for use in the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
MX2021003681A true MX2021003681A (es) 2021-08-19

Family

ID=68468802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003681A MX2021003681A (es) 2018-10-03 2019-10-02 Composiciones y metodos para el tratamiento de desordenes inflamatorios.

Country Status (11)

Country Link
US (1) US20210369678A1 (es)
EP (1) EP3860593A1 (es)
JP (1) JP2022504293A (es)
KR (1) KR20210100594A (es)
CN (1) CN113382729A (es)
AU (1) AU2019355097A1 (es)
CA (1) CA3114592A1 (es)
MX (1) MX2021003681A (es)
SG (1) SG11202103191QA (es)
TW (1) TW202027745A (es)
WO (1) WO2020072645A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
US20230218592A1 (en) 2020-04-20 2023-07-13 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
KR20230146812A (ko) 2022-04-13 2023-10-20 재단법인 대구경북첨단의료산업진흥재단 아릴에텐 유도체를 유효성분으로 포함하는 염증성 장질환 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101420957B (zh) * 2006-04-13 2011-04-13 大鹏药品工业株式会社 炎症性肠病治疗药
RU2531354C2 (ru) * 2008-04-28 2014-10-20 Янссен Фармацевтика Нв Бензоимидазолы как ингибиторы пролилгидроксилазы
MX2017001293A (es) * 2014-07-28 2017-05-23 Nogra Pharma Ltd Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino.

Also Published As

Publication number Publication date
SG11202103191QA (en) 2021-04-29
EP3860593A1 (en) 2021-08-11
US20210369678A1 (en) 2021-12-02
WO2020072645A1 (en) 2020-04-09
AU2019355097A1 (en) 2021-05-27
CA3114592A1 (en) 2020-04-09
CN113382729A (zh) 2021-09-10
JP2022504293A (ja) 2022-01-13
TW202027745A (zh) 2020-08-01
KR20210100594A (ko) 2021-08-17

Similar Documents

Publication Publication Date Title
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
PH12021550043A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño